Volasertib Receives Breakthrough Therapy Designation for AML

Share this content:

Boehringer Ingelheim announced that the FDA has granted Breakthrough Therapy designation to volasertib for the treatment of patients ≥65 years old with previously untreated acute myeloid leukemia (AML), ineligible for intensive remission induction therapy. Volasertib is an investigational inhibitor of polo-like kinase (Plk), designed to inhibit the activity of Plk1, an enzyme in the Plk family that regulates cell division resulting in prolonged cell cycle arrest, ultimately leading to cell death.

RELATED: Hematologic Cancers Resource Center

Results from a Phase 2 study in newly diagnosed patients with AML considered ineligible for intensive remission induction therapy, demonstrated higher rates of objective response and an improvement in event-free survival in patients receiving volasertib in combination with low-dose cytarabine (LDAC) compared to patients receiving LDAC alone.

These results led to the initiation of a Phase 3 trial, POLO-AML-2 in January 2013. This trial is designed to assess the efficacy and safety of volasertib in combination with LDAC, compared to placebo in combination with LDAC, in patients ≥65 years old with previously untreated AML, ineligible for intensive remission induction therapy. The trial is currently enrolling eligible patients.

For more information call (800) 542-6257 or visit Boehringer-Ingelheim.com

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs